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ABSTRACT Whether the interaction between the gut microbiota and the immune
response influences the evolution of cirrhosis is poorly understood. We aimed to in-
vestigate modifications of the microbiome and the immune response during the
progression of cirrhosis. Rats were treated with carbon tetrachloride (CCl4) to induce
cirrhosis. We then assessed microbiome load and composition in stool, ileocecal con-
tents (ICCs), mesenteric lymph nodes (MLNs), blood, and ascitic fluids (AFs) at 6, 8,
and 10 weeks or ascites production and measured cytokine production in MLNs and
blood. The microbiome of MLN, blood, and AF showed a distinct composition com-
pared to that of stool and ICCs. Betaproteobacteria (Sutterella) were found associated
with the appearance of a decompensated state of cirrhosis. Microbial load increased
and showed a positive correlation with the relative abundance of pathobionts in the
MLN of decompensated rats. Among several genera, Escherichia and “Candidatus Ar-
thromitus” positively correlated with elevated levels of systemic proinflammatory cy-
tokines. “Candidatus Arthromitus,” a segmented filamentous bacteria, was detected
in ICC, MLN, and AF samples, suggesting a possible translocation from the gut to
the AF through the lymphatic system, whereas Escherichia was detected in ICC, MLN,
AF, and blood, suggesting a possible translocation from the gut to the AF through
the bloodstream. In the present study, we demonstrate that microbiome changes in
distinct intestinal sites are associated with microbial shifts in the MLNs as well as an
increase in cytokine production, providing further evidence of the role the gut-liver-
immunity axis plays in the progression of cirrhosis.
IMPORTANCE Cirrhosis severity in patients was previously shown to be associated
with progressive changes in the fecal microbiome in a longitudinal setting. Recent
evidence shows that bacterial translocation from the gut to the extraintestinal sites
could play a major role in poor disease outcome and patient survival. However, the
underlying mechanisms involving the microbiota in the disease progression are not
well understood. Here, using an animal model of cirrhosis in a longitudinal and mul-
tibody sites setting, we showed the presence of a distinct composition of the micro-
biome in mesenteric lymph nodes, blood, and ascitic fluid compared to that in feces
and ileocecal content, suggesting compartmentalization of the gut microbiome. We
also demonstrate that microbiome changes in intestinal sites are associated with
shifts in specific microbial groups in the mesenteric lymph nodes as well as an in-
crease in systemic cytokine production, linking inflammation to decompensated cir-
rhosis in the gut-liver-immunity axis.
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Cirrhosis is defined as the presence of fibrosis and regenerating nodules in the liverdue to various causes such as alcohol, hepatitis viruses, metabolic syndrome, or
immune dysfunction. Cirrhosis can lead to portal hypertension and liver insufficiency
and their related complications, such as ascites, infections, hepatic encephalopathy,
hepatorenal syndrome, variceal bleeding, and acute-on-chronic liver failure (ACLF) (1).
Before the development of complications, patients are considered to have “compen-
sated cirrhosis,” and when complications develop, they are considered having “decom-
pensated cirrhosis,” which has a poorer prognosis than the compensated stage (2).
Patients with cirrhosis present alterations in their fecal microbiome composition
compared to that of healthy individuals, which could be of oral origin of some
potentially pathogenic species (3, 4). The cross talk between the gut microbiome and
the immune system may contribute to the development of health complications, which
therefore may lead to the evolution from compensated to decompensated stages (5, 6).
The intestinal microbiota, which harbors bacteria, archaea, and eukarya, is known to
play a pivotal role in the development of the host immune system and in the
maintenance of host intestinal homeostasis by modulating immune responses to
pathogens and by maintaining the integrity of intestinal barrier functions (7). Com-
mensal bacteria are transported from the intestines by dendritic cells (DCs) through the
lymphatic system to the mesenteric lymph nodes (MLNs), which form part of the
gut-associated lymphatic tissue (GALT) and act as the first line of immune defense
against pathogens from the intestines (8–10). In the MLNs, bacteria are maintained at
low levels by the host mucosal immune system (11). The translocation of bacteria into
MLNs has been investigated in other disorders, including Crohn’s disease and ulcerative
colitis (12, 13), where a distinct microbial community composition was observed
between the two inflammatory disorders.
Patients with cirrhosis present alterations in the gut microbiota, intestinal permea-
bility, and immune response, leading to bacterial translocation, which is the paracellular
passage of bacteria from the intestinal lumen through the intestinal wall to the MLNs
or other sites (10, 11, 14–16). Bacterial translocation then activates the gut-liver-
immune axis, which stimulates the induction of proinflammatory cytokines, further
perpetuating increased intestinal permeability and thus bacterial translocation (17).
Pathogen-associated molecular patterns (PAMPs), such as the endotoxin lipopolysac-
charide (LPS) found on the cell membranes of Gram-negative bacteria, bind to pattern
recognition receptors (PRRs) such as Toll-like receptors (TLRs), causing an induction of
proinflammatory cytokines such as tumor necrosis factor alpha (TNF-) and interleukin
6 (IL-6), which tend to be elevated in patients with cirrhosis (18). MLNs also produce
TNF- in response to bacterial translocation, especially in patients with ascites (9, 18,
19). Ascites is a common complication in advanced cirrhosis that is associated with a
high mortality rate and is caused by portal hypertension, leading to fluid accumulation
in the abdomen. It has been hypothesized that elevated TNF- production causes
hemodynamic disturbances, leading to splanchnic vasodilatation through nitric oxide
synthesis stimulation. This could contribute to altered intestinal barrier function, re-
sulting in bacterial translocation (9, 20), which has been frequently observed in cirrhotic
patients with ascites. Additionally, ascites has been shown to increase the susceptibility
of host bacterial infection (17), likely due to the fact that TNF- has been shown to
loosen tight junction proteins of intestinal epithelial cells, perpetuating bacterial trans-
location and subsequently an inflammatory response (10).
Bajaj et al. showed that cirrhosis severity in patients was associated with progressive
changes in the gut microbiome in a longitudinal study (5). In fact, recent evidence
showed that bacterial translocation from the intestines could play a major role in poor
disease outcome and patient survival (21, 22). However, the underlying mechanisms
that involve the gut microbiota in the disease progression are not well understood.
Therefore, the aims of this study were to (i) investigate the spatial and temporal
changes of the composition of the microbiome in a cirrhosis rat model, (ii) evaluate
changes of the microbiome related to the progression of cirrhosis, and (iii) assess the
immune modulation by the microbiome detected in extraintestinal sites.
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RESULTS
We studied 15 control rats at weeks 6 (n  5), 8 (n  5), and 10 (n  5), 25
CCl4-treated rats sacrificed at weeks 6 (n  9), 8 (n  8), and 10 (n  8) of CCl4 cirrhosis
induction that were considered rats under induction of cirrhosis or compensated
CCl4-treated rats, and 19 CCl4-treated rats when they developed ascites that were
considered rats with decompensated cirrhosis. The scores of liver damage in the
different groups were the following. All control rats showed score 0; in week-6 rats, six
rats had scores of 2 and three had scores of 1. In week-8 rats, six rats had scores of 2
and two had scores of 1. In week-10 rats, seven rats had scores of 2 and one had a score
of 1. In ascitic rats, 14 rats had scores of 2 and five had scores of 3 (P  0.048 for
week-10 rats, P  0.019 for week-8 rats, and P  0.007 for week-6 rats). Bacterial
cultures were negative in all control rats, week-6 rats, and week-8 rats and were positive
in two week-10 rats (both in MLNs) and in five ascitic rats (P  0.05 between ascitic rats
and control rats). These five ascitic rats presented a total of nine positive cultures: in
MLNs in four rats, in livers and spleens in three rats, and in ascitic fluid in two rats.
Isolated bacteria were Escherichia coli in all rats with positive cultures, except one ascitic
rat in which Enterococcus spp. grew.
Compartmentalization of microbial communities. To assess the existence of a
compartmentalized microbiome (meaning a specific microbial community at different
body sites), we compared the microbiome compositions of various body sites from all
rats of the study: intestinal sites such as feces (F) and ileocecal content (ICC) and
extraintestinal sites such as MLN, blood, and ascitic fluid (AF). Feces and ICC specimens
from control rats presented similar microbial communities (P  0.44; permutational
multivariate analysis of variance [PERMANOVA] test) (Fig. 1AB) dominated by Firmicutes
(means of 61% and 78%, respectively), Bacteroidetes (means of 35% and 20%, respec-
tively), Actinobacteria (means of 1% and 0.04%, respectively), and Proteobacteria (means
of 0.3% and 0.4%, respectively). The microbiome of MLN, blood, and AF showed a
distinctive composition compared to that of feces and ICC (P  0.0001; PERMANOVA
test) (Fig. 1A). MLNs and blood displayed similar microbial communities (P  0.616;
PERMANOVA test) dominated by Firmicutes (48% and 50%, respectively), Bacteroidetes
(43% and 37%, respectively), Proteobacteria (3% and 2%, respectively), and Actinobac-
teria (3% and 5%, respectively) (Fig. 1B). A comparison between control and CCl4-
treated rats in the different body sites showed significant differences.
Longitudinal study: evolution of cirrhosis and microbiome modification. To
evaluate the evolution of the microbiome in parallel with the progression of cirrhosis,
rats were sacrificed to collect ICC, MLNs, and blood at different time points (6, 8, and
FIG 1 Spatial microbial community compositions in control and CCl4-treated rats. (A) Weighted principal coordinate analysis (PCoA) UniFrac metrics (taxonomic
clustering). (B) Relative abundance at the phylum level; n  23 for stool, n  59 for ICC, n  46 for MLN, n  57 for blood, and n  15 for AF.
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10 weeks after the initiation of CCl4 treatment and at ascites development for the
CCl4-treated group and at matched time points for the control group). For the collec-
tion of samples, groups of animals were sacrificed at different time points. We found
significant changes in the microbiome compositions in ICC and MLN samples that were
associated with the progression of cirrhosis.
In the ICC samples, CCl4-treated rats showed an increase in Betaproteobacteria
(P  0.01, q  0.098) and Erysipelotrichia (P  0.001, q  0.012; Kruskal-Wallis test) at
weeks 6 and 8 of CCl4 treatment in comparison to control rats (Fig. 2A). At week 10,
both groups of bacteria significantly decreased compared to that at weeks 6 and 8.
When rats developed ascites, Erysipelotrichia almost disappeared, whereas Betaproteo-
bacteria increased again. Both groups of bacteria were absent in control rats. At the
genus level, Sutterella and Coprococcus increased (P  0.001, q  0.02; Kruskal-Wallis
test) in decompensated rats compared to that in controls (Fig. 2B). At 6, 8, and 10 weeks
after the initiation of CCl4 treatment, rats without ascites presented an intermediate
relative abundance of all these genera. The Allobaculum genus belonging to the
Erysipelotrichia family is known as a potentially beneficial bacterial group (23) and
showed an increase in the compensated CCl4-treated rats but disappeared when they
presented ascites (P  0.0002, q  0.018; Kruskal-Wallis test). These results suggest that
groups of potentially beneficial bacteria, such as Allobaculum, attempted to outcom-
pete pathogenic ones in the ileocecum such as Sutterella, which belongs to Betapro-
teobacteria. However, Allobaculum seemed to be unable to outcompete Sutterella in the
ICC when rats presented ascites. Additionally, “Candidatus Arthromitus,” a genus from
the Firmicutes phylum, showed high relative abundance only in decompensated rats
compared to that in compensated CCl4-treated rats and control rats (P  0.023,
q  0.15; Kruskal-Wallis test) (Fig. 2C).
In MLN samples from decompensated rats (with ascites), only one bacterial genus,
“Candidatus Arthromitus,” showed a significantly high relative abundance compared to
that from control and compensated CCl4-treated rats (P  0.0002, q  0.019; Kruskal-
Wallis test) (Fig. 3A and B). “Candidatus Arthromitus” was identified in 26% (4 of 15) of
the AF samples, in only 5% of blood samples (4 of 73), and was not found in stool
samples (Fig. 3C).
In feces, Coprococcus, Sutterella, and Allobaculum showed some differences in their
relative abundances between the three groups of rats (controls, compensated, and
decompensated), but none of the differences were significant (q  0.2; Kruskal-Wallis
test). In blood samples, the Spirochaetes phylum was found in a high proportion in the
decompensated group compared to that in the two other groups (P  0.001, q  0.035;
Kruskal-Wallis test).
Using the weighted UniFrac distance, a metric used to compare microbial commu-
nity compositions between samples, we compared the stability of the microbiome in
ICC, MLN, and blood samples from rats under induction of cirrhosis without ascites
(compensated CCl4-treated rats) with that from rats with ascites (rats with decompen-
sated cirrhosis). We observed a decreased stability of the microbiome composition of
rats with ascites in blood samples (P  0.04; Mann-Whitney test) (see Fig. S1 in the
supplemental material), but the difference was not significant in ICC and MLN samples.
Microbial load. To complement our findings on relative abundance of the se-
quenced 16S rRNA genes, we evaluated the microbial load using real-time quantitative
PCR of the 16S rRNA genes. Microbial load, as measured by 16S rRNA gene quantitative
PCR (qPCR), was significantly higher in the MLNs from cirrhotic decompensated rats
than from control rats (P  0.008; Mann-Whitney test), positively correlated with the
relative sequence abundance of Proteobacteria (  0.673, P  0.002; Spearman test),
and negatively correlated with the relative abundance of Bacteroidetes (  0.637,
P  0.004; Spearman test) (Fig. 4).
Correlation between microbiome and cytokine levels. The progression toward
decompensated cirrhosis is associated with a high production of proinflammatory
cytokines, such as TNF-, IL-17, and IL-6, as well as anti-inflammatory cytokines such as
Santiago et al.
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FIG 2 Microbial groups in ileocecal contents (ICC) samples involved in the severity of cirrhosis. (A) Temporal taxonomic differences between controls and
CCl4-treated rats. Two classes of bacteria, Erysipelotrichia (P  0.001, q  0.012) and Betaproteobacteria (P  0.01, q  0.098), presented significantly different
relative abundances over time between the control and the CCl4-treated groups. Statistics were performed using the Kruskal-Wallis test. (B) Taxonomic
differences between controls and CCl4-treated rats with ascites and CCl4-treated rats before development of ascites. Two bacterial genera, Coprococcus
(P  0.0001, q  0.011) and Sutterella (P  0.0005, q  0.014), were found in higher relative abundances in CCl4-treated rats than in control rats. Two bacterial
genera, Desulfovibrio (P  0.002, q  0.025) and Ruminococcus (P  0.0007, q  0.013), were found in higher relative abundances in control rats than in
CCl4-treated rats. Allobaculum was found in higher relative abundance (P  0.0004, q  0.013) only in compensated CCl4-treated rats, and “Candidatus
Arthromitus” (P  0.023, q  0.15) was in higher relative abundance in decompensated cirrhotic rats. Statistics were performed using the Kruskal-Wallis test.
Microbiome Associated with Cirrhosis Complications
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FIG 3 Detection of “Candidatus Arthromitus” in spatial and temporal settings. (A) “Candidatus Arthromitus” was found in higher relative abundance
in mesenteric lymph nodes of decompensated rats (P  0.0002, q  0.018). (B) “Candidatus Arthromitus” was found in 72% (13 of 18) of mesenteric
lymph node samples of decompensated rats. (C) “Candidatus Arthromitus” was detected in ileocecal content (ICC), mesenteric lymph node (MLN),
blood, and ascitic fluid (AF) samples but not in feces (F). 6W, 6 weeks; 8W, 8 weeks; 10W, 10 weeks.
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IL-10 (24, 25). Using enzyme-linked immunosorbent assays (ELISAs), we measured
serum and MLN levels of these cytokines. To evaluate a possible correlation between
the inflammatory status and the microbial community composition, we used Spearman
correlation tests to associate levels of the proinflammatory cytokine IL-17 in MLNs and
the ratios of systemic IL-6/IL-10 and systemic TNF-/IL-10 with the relative abundance
of microbial groups in MLNs. Ratios between pro- and anti-inflammatory cytokines have
been extensively used as biomarkers to associate an immune response with the
characteristics of multiple pathologies, including liver disease. The use of ratios reduces
significantly the individual variability of single cytokine production. We found a positive
correlation between the IL-6/IL-10 ratio and the relative abundance of Escherichia
(  0.79, P  9.2e5; Spearman test) and positive correlations between the TNF-/
IL-10 ratio and the relative abundances of Escherichia (  0.57, P  0.01; Spearman
test) and “Candidatus Arthromitus” (  0.72, P  0.001; Spearman test) (Fig. 5A). Since
each microorganism provides a particular array of PAMPs to signal the immune system,
the final result is not necessarily a generalized increase of pro- or anti-inflammatory
cytokines. In the particular case of “Candidatus Arthromitus,” the association of one
ratio but not the other (both having in common IL-10) implies that this microorganism
is more involved in the production/regulation of TNF than of IL-6. We also found
positive correlations between levels of IL-17 and several different microbial genera,
such as those belonging to Proteobacteria (Pseudomonas, Burkholderia and Sutterella)
FIG 4 Quantification of the microbiota by real-time PCR on the 16S rRNA gene and correlation with microbiome composition. (A) Microbial
load in ileocecal content (ICC) samples was higher in decompensated cirrhotic rats than in control and compensated CCl4-treated rats and was
significantly higher in the mesenteric lymph nodes (MLNs) of decompensated cirrhotic rats than in control rats (P  0.008; Mann-Whitney test).
In both ICCs and MLNs: n  8 for controls (CTL), n  8 for compensated CCl4-treated rats, n  7 for decompensated cirrhotic rats. (B) Spearman
correlation between microbial load and relative abundance of Bacteroidetes (  0.637, P  0.004) and between microbial load and relative
abundance of Proteobacteria (  0.673, P  0.002) in the MLNs.
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and “Candidatus Arthromitus,” and negative correlations between levels of IL-17 and
Parabacteroides and Coprococcus (Fig. 5B). “Candidatus Arthromitus” and Escherichia
were both detected in ICC, MLN, and AF samples, but only Escherichia was detected in
blood samples from rats (Fig. 6).
DISCUSSION
In this study, we showed that microbiome changes in distinct intestinal sites are
associated with microbial shifts in the MLNs as well as an increase in cytokine produc-
tion that correlated with disease progression in rats with experimental cirrhosis. The
main results of the present work are the characterization of the sequential changes of
the microbiome in the progression of cirrhosis and, in particular, the cross talk between
the microbiome and the host immune system using a rat model in a longitudinal and
multibody sites study setting.
Loss of intestinal barrier function, dysbiosis, and systemic immune dysfunction
characterize cirrhosis (17). Bacterial translocation is a result of a loss of intestinal barrier
function and is considered a biomarker for cirrhosis progression and decompensation,
in which intestinal bacteria travel by paracellular transport through the permeable
epithelial cells to the portal vein, the liver, and systemic circulation, causing an
inflammatory response (10). It has been demonstrated that microorganisms are also
FIG 5 Correlations between proinflammatory cytokines and relative abundances of genera in MLNs. (A) Positive Spearman correlations were found between
the ratio of systemic IL-6/IL-10 and Escherichia and between the ratio of systemic TNF-/IL-10 and Escherichia and “Candidatus Arthromitus.” (B) Spearman
correlations between IL-17 levels measured in mesenteric lymph nodes (MLNs) and relative abundances of genera detected in MLNs.
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transported by dendritic cells from the intestines to the MLNs via the lymphatic system
(11, 26, 27). Comparing the compositions of intestinal and extraintestinal body sites, our
findings suggest a loss of barrier function in which a specific microbial community,
particularly Proteobacteria and Actinobacteria, was transported from the intestine to
MLNs, blood, and AF, which caused an induction of proinflammatory cytokines such as
TNF-, IL-6, and IL-17 in rats. This inflammatory response was associated with disease
progression and decompensation with ascites formation.
It has been suggested that dysbiosis, which is the unfavorable shift in the microbiota
community structure that compromises microbe-host homeostasis, is a major driver of
cirrhosis and is also a major contributor to bacterial translocation to MLNs in cirrhosis
animal models (10, 28). In the present study, we found more microbiome alterations in
ICC than in fecal samples of rats with decompensated cirrhosis. This suggests that ICC
samples may be more appropriate than fecal samples to detect microbiome compo-
sition alterations with smaller cohorts. This is in line with previous studies in patients
suggesting that dysbiosis in advanced cirrhosis mainly occurs in upper areas of the
intestine such as the ileum (10) as well as with the finding that microbiota analyses in
fecal samples do not accurately represent dysbiosis in sigmoid mucosal samples
obtained by biopsy during sigmoidoscopy (29). In the present study, ICC samples from
CCl4-treated rats showed an attempt of beneficial groups of bacteria, such as Erysip-
elotrichia, to outcompete potential pathobionts such as Sutterella, which belongs to
Betaproteobacteria. A pathobiont is defined as a symbiont that under certain circum-
stances becomes a pathogen (30). This compensation failed when liver damage and
inflammation increased and rats developed ascites, a condition associated with an
increase of inflammatory markers, an increase in the relative abundance of Escherichia
in all sample types except in stool, and an increase in the load of Proteobacteria in
MLNs.
Bajaj et al. (5) characterized the composition of the fecal microbiome in patients
with compensated and decompensated cirrhosis and also evaluated the stability of the
microbiome composition at two time points within an interval of 6 months. Our
findings confirmed their claim that the level of dysbiosis in stool samples was associ-
ated with cirrhosis progression, whereas a relatively stable microbiome composition
over time was associated with stable disease. Additionally, the use of an animal model
allowed us to unravel the possible cross talk between the microbiome in MLNs and the
immune system that was confirmed through a correlation analysis between microbial
genera identified in MLNs and levels of proinflammatory cytokines such as TNF-, IL-6,
and IL-17 in MLNs or blood. Moreover, our results are congruent with a comprehensive
study that analyzed 29 different cytokines from 522 cirrhotic patients, indicating that
systemic inflammation is likely the underlying cause of decompensation and acute-on-
chronic liver failure in cirrhosis (8). Finally, our findings are supported by the recent
FIG 6 Detection of 16S sequences of Escherichia in rat samples. ICC, ileocecal content; MLN, mesenteric lymph
node; AF, ascitic fluid; F, feces.
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work of Muñoz et al. (6) that also demonstrated the appearance of a proinflammatory
immune response driven by gut dysbiosis in decompensated cirrhosis.
We also observed a positive correlation between the abundance of Escherichia,
which belongs to the Proteobacteria phylum, in MLNs and proinflammatory cytokines,
confirming the results of previous studies using culture techniques and PCR of the 16S
rRNA gene and making Escherichia a potential biomarker for cirrhosis progression (31).
We have further demonstrated that an increase in overall microbial load was associated
with an increase in Proteobacteria in the MLNs of decompensated cirrhotic rats com-
pared to that in controls and in compensated CCl4-treated rats, suggesting an increase
in Proteobacteria not only in relative abundance but also in absolute amount.
Furthermore, we observed that “Candidatus Arthromitus,” a genus from the Firmi-
cutes phylum that positively correlated with IL-17 levels, was found in higher abun-
dance in the MLNs of rats with decompensated cirrhosis than in control rats and
compensated CCl4-treated rats. This genus was detected in all sample types except
feces, which again confirms that the use of stool samples would not have led to the
detection of this genus in a decompensated state. “Candidatus Arthromitus” is a
segmented filamentous bacterium (SFB) that can induce multiple adaptive immune
responses, especially in Th17 cells in the small intestinal lamina propria of mice (32, 33).
Th17 cells that produce the effector cytokine IL-17 are potent inducers of tissue
inflammation and have been associated with the pathogenesis of many immune-
mediated diseases (34). Therefore, “Candidatus Arthromitus” might play an important
role in inducing inflammation, which may lead to a decompensated state. This genus
is also well known to be refractory to in vitro culture techniques (35, 36), which explains
why it has not been uncovered in previous studies using traditional culture techniques.
This genus, which was not detected in feces and in only few blood samples, might have
reached the MLNs via the lymphatic system after possible translocation in the upper
regions of the gastrointestinal (GI) tract, such as the ileocecal region. Escherichia,
differently from “Candidatus Arthromitus,” was detected in all sample types, including
in all blood samples, suggesting that its translocation to AF might be via the blood-
stream.
Since this work was performed on animals, we may not be able to extrapolate all the
findings to cirrhotic patients, particularly in terms of the involvement of specific genera
such as “Candidatus Arthromitus,” as the microbiome might present differences in its
composition. However, our study should pave the way for the search for an equivalent
genus to “Candidatus Arthromitus” in humans that is involved in inducing inflammation
in cirrhotic patients. Also, the limited numbers of animals per group might be the
reason why we did not find significant changes in fecal samples after multiple testing
correction but rather a trend, compared to that of previous findings in human fecal
samples (4, 37). Another limitation of our study might be the use of a unique liver
disease animal model, as different etiologies might lead to different changes in the
microbiome as shown by Fouts et al. (38). However, although different microbial groups
might be involved in the progression of cirrhosis depending on the animal model used,
our study mainly focused on the sequential changes in the microbiome in distinct
intestinal sites and their association with inflammation in an advanced stage of
decompensated cirrhosis. This limitation may apply to any animal models used to
understand human disease.
In conclusion, our study confirmed previous studies showing that the alterations in
the gut microbial community involved an increase of the ratio of pathobionts to
beneficial bacteria (39) and also showed that this reflects dysbiosis present in extraint-
estinal sites such as MLNs, where direct cross talk between the microbiota and the
immune cells takes place.
MATERIALS AND METHODS
Experimental design. (i) Animals. Male Sprague-Dawley rats weighing 35 to 49 g were purchased
from Harlan Laboratories (Indianapolis, IN, USA) and provided by Research Models and Services Produc-
tion (Udine, Italy). After the rats were weaned from their mothers, they were fed a rodent chow diet
(2018S; Teklad, Madison, WI, USA). After 1 week of quarantine, all animals were placed in individual cages
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and kept at a constant room temperature of 21°C, exposed to a 12-h light:12-h dark cycle and allowed
free access to water and rodent chow (A04; SAFE, Augy, France). One week later, phenobarbital
(1.5 mmol/liter) (Luminal; Kern Pharma, Barcelona, Spain) was added to the tap water given to all animals.
There was no contact between rats via water, chow, or feces.
(ii) Induction of cirrhosis and study groups. Cirrhosis was induced as previously described (40).
When rats reached a weight of 200 g, they were administered weekly doses of CCl4 (Sigma-Aldrich, St.
Louis, MO., USA) intragastrically using a sterile pyrogen-free syringe (ICO plus 3; Novico Médica, S.A.,
Barcelona, Spain) with an attached stainless-steel animal feeding tube (Popper and Sons, New Hyde Park,
NY, USA) without anesthesia. The first dose of CCl4 was 20 l, and subsequent doses were adjusted on
the basis of changes in weight 48 h after the previous dose. When rats presented ascites, the dose of CCl4
was maintained at 40 l.
We designed different groups of CCl4-treated rats for which laparotomy and sample collection were
performed at four different time points: after 6, 8, and 10 weeks of the first dose of CCl4 and when ascites
was suspected by the increase in abdominal girth and confirmed by paracentesis. A control group of rats
not treated with CCl4 was also included, and samples were collected at the same three time points (6,
8, and 10 weeks) as for the cirrhotic group.
Paracentesis was performed under air anesthesia with isoflurane (Forane; Abbott, Madrid, Spain)
under sterile conditions, and approximately 0.1 ml of ascitic fluid was removed. One week later, a
laparotomy was carried out.
(iii) Laparotomy. Laparotomy was carried out on all CCl4-treated rats and on control rats at weeks
6, 8, and 10 or when ascites was suspected. For laparotomy, rats were anesthetized with 10 mg/kg
xylazine (Rompun; Bayer, Kiel, Germany) and 50 mg/kg ketamine (Ketolar; Parke-Davis, Madrid, Spain)
under sterile conditions. In brief, the abdominal fur was removed with a depilatory cream (Deliplus;
Mercadona, Spain) and the skin was sterilized with iodine (Curadona; Lainco, Spain). The abdomen was
then opened via a 4-cm median incision, and the remaining fluid was removed.
Biological sample collection. The sequence of sample collection at laparotomy was stool (before
laparotomy), MLN, blood, liver spleen, and ileocecal content (ICC). Samples from CCl4-treated and control
rats were stored frozen at 80°C until microbiome analysis. Blood and MLN samples were also used for
cytokine analysis.
Bacterial cultures. We inoculated samples of homogenized mesenteric lymph nodes, ascitic fluid,
pleural fluid, spleens, and livers on Columbia blood agar, Columbia CNA agar, and the chromogenic
medium CPS ID3 (bioMérieux, Marcy-l’Étoile, France). Cultures were incubated for 48 h at 37°C in an
aerobic atmosphere. The isolated bacteria were presumptively identified according to their pattern of
growth and morphology (41).
Liver damage. Histological liver damage was evaluated by hematoxylin-eosin and Masson’s
trichrome staining of 4-m slices from paraffin blocks. A single expert pathologist blindly classified the
liver samples according to a semiquantitative score: 0, normal; 1, fibrosis with porto-portal fibrous tracts;
2, regeneration nodules with thin complete fibrous tracts; and 3, regeneration nodules with thick and
complete fibrous tracts (41).
Cytokine measurement. TNF-, IL-6, and IL-10 cytokines were determined in blood samples and
IL-17 in MLNs by enzyme-linked immunosorbent assays (ELISAs) according to the manufacturer’s
protocols (eBiosciences). Results are expressed as picograms per milliliter in blood samples and the ratio
of picograms of IL-17 per milligram of total protein. Limits of detection were 30 pg/ml for TNF-, IL-6, and
IL-17 and 15 pg/ml for IL-10.
Microbiome analysis. (i) Genomic DNA extraction. All biological specimens were processed for
genomic DNA extraction using protocols previously described by Santiago et al. (42) for low biomass
samples such as MLN, blood, and AF and a protocol recommended by the International Human
Microbiome Standard for stool samples (http://www.microbiome-standards.org/).
(ii) 16S rRNA genes gene sequencing. To prepare the DNA for sequencing, we amplified a fragment
of the 16S rRNA gene by PCR using universal primers targeting the V4 hypervariable region as previously
described (43). Amplicons were then purified using the QIAquick PCR purification kit (Qiagen, Barcelona,
Spain), quantified using a NanoDrop ND-1000 spectrophotometer (Nucliber), and then pooled in equal
concentrations. The pooled amplicons (2 nM) were then subjected to sequencing using Illumina MiSeq
technology at the technical support unit of the Autonomous University of Barcelona (UAB, Spain)
according to standard Illumina platform protocols.
(iii) Microbiome composition analysis. To analyze the microbiome composition, we first loaded
the raw sequences into the QIIME 1.9.1 pipeline, as described by Navas-Molina et al. (44). Low-quality
sequence reads were filtered out by applying default settings and a minimum Phred score of 20.
From the filtering step and a total of 214 samples, we obtained a total of 2.5 million high-quality
sequences with an average number of reads of 11,899. We used the USEARCH algorithm to cluster
similar filtered sequences into operational taxonomic units (OTUs) based on a 97% similarity
threshold. We then identified and removed chimeric sequences using UCHIME. Representative
sequences were selected and aligned using PyNAST against Greengenes template alignment
(gg_13_8 release), and a taxonomical assignment step was performed using the basic local align-
ment search tool to map each representative sequence against a combined database encompassing
the Greengenes and PATRIC databases.
For  diversity analysis, we rarefied to 1,046 sequences per sample when comparing all samples
simultaneously. When analyzing only low-biomass samples, we rarefied them at 1,046 sequences per
sample and at 9,396 sequences per sample when analyzing stool and ICC samples. Rarefaction is
used for cases in which read counts are not similar in numbers between samples. Weighted and
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unweighted UniFrac metrics were applied to build phylogenetic distance matrices, which were then
used to construct hierarchical cluster trees using a principal-coordinate analysis (PCoA) represen-
tation.
(iv) Microbial load assessment. To quantify microorganisms, the extracted genomic DNA was used
to amplify the V4 region of the 16S rRNA gene by quantitative real-time PCR (qPCR) using the following
primers: V4F_517_17 (5=-GCCAGCAGCCGCGGTAA-3=) and V4R_805_19 (5=-GACTACCAGGGTATCTAAT-3=).
To calibrate the qPCR reactions, calculated amounts of a linearized plasmid containing the V4 region of
the 16S rRNA gene were used. Plasmid concentration was measured using a NanoDrop ND-1000
spectrophotometer (Nucliber), and the number of plasmid copies was calculated from the plasmid’s
molecular weight. To extrapolate the bacterial number in each sample, serial dilutions of the plasmid
were amplified. The qPCR was performed with the 7500 Fast Real-Time PCR system (Applied Biosystems)
using optical-grade 96-well plates. The PCR was performed in a total volume of 25 l using the Power
SYBR green PCR master mix (Applied Biosystems) containing 100 nM each of the universal forward and
reverse primers. The reaction conditions for amplification of DNA were 50°C for 2 min, 95°C for 10 min,
and 40 cycles of 95°C for 15 s and 60°C for 1 min. All reactions were performed in triplicates, and mean
values were calculated. This experiment was also duplicated to ensure accuracy. Mean values from both
experiments were taken into account. Data were analyzed using Sequence Detection Software version
1.4, supplied by Applied Biosystems.
Statistical analysis. We performed statistical analyses under QIIME and R. We used the D’Agostino-
Pearson test to check for the normality of the data distribution. Parametric normally distributed data
were compared by Student’s t tests for paired or unpaired data; otherwise, the Wilcoxon signed rank test
was used for paired data and the Mann-Whitney U test for unpaired data. Qualitative variables were
analyzed by Fisher’s exact test. The Kruskal-Wallis one-way test of variance was used to compare the
mean numbers of sequences from different unpaired groups of subjects at various taxonomic levels, the
Wilcoxon test was used when comparing only 2 groups. We performed analyses with the nonparametric
multivariate ANOVA (PERMANOVA) called the Adonis test to test for differences in microbial communities
using the UniFrac metrics. We performed Spearman tests to evaluate correlations between microbiome
composition and biological parameters such as cytokine levels. When possible, the analysis provided
false discovery rate (q)-corrected P values (q values). A q value of 0.05 was considered significant for
all tests.
Ethics approval. The study was approved by the Animal Research Committee at the Institut de
Recerca of Hospital de la Santa Creu i Sant Pau (Barcelona) and by the Department of Agriculture,
Livestock and Fisheries of the Generalitat de Catalunya (Departament d’Agricultura, Ramaderia i Pesca).
Animal care complied with the criteria outlined in the Guide for the Care and Use of Laboratory Animals
(Committee for the Update of the Guide for the Care and Use of Laboratory Animals Institute for
Laboratory Animal Research Division on Earth and Life Studies, Washington, DC, USA).
Data availability. Sequence data have been deposited in the NCBI database under accession
number PRJNA448565.
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